Opinion: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars

First Opinion The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars By Dan Leonard Nov. 6, 2021
Reprints
Adobe
A mericans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs.

Read the source article at statnews.com
2021-11-06 16:12:46

You might also be interested in:

Call for Papers: Essen Health Conference 02/21/2022
Telehealth Could Advance Value-based Care in the US 12/15/2021
Evidence Partners and Clarivate Form Channel Partnership to… 02/01/2022
Fables And Misperceptions About Drug Makers And Drug Pricing… 02/22/2022
Brii Bio Appoints Coy Stout as Senior Vice President and Head… 10/01/2021
COVID-19 Pandemic Shines Spotlight on Vaccine Pricing Strategies 05/18/2021
Value & Outcomes Spotlight: Using RWE/RWD to Drive Health Policy 04/05/2022